Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    China Tightens National Sovereignty and Cyber Defenses Through Localized Inspections

    Trump’s border czar says vetting of ICE officer is under internal review after Maine shooting

    Red Sea shipping slows after Houthi attack on Saudi Arabia, data shows

    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest VKontakte
    Sg Latest NewsSg Latest News
    • Home
    • Politics
    • Business
    • Technology
    • Entertainment
    • Health
    • Sports
    Sg Latest NewsSg Latest News
    Home»Health»LNTH) and Encourages Investors with Substantial Losses to Contact the Firm
    Health

    LNTH) and Encourages Investors with Substantial Losses to Contact the Firm

    AdminBy AdminNo Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    NEWTOWN, Pa., Sept. 11, 2025 /PRNewswire/ — Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), resulting from allegations of providing potentially misleading business information to the investing public.

    If you have information that could assist in the Lantheus investigation or if you are a Lantheus investor who suffered a loss and would like to learn more, you can provide your information HERE.

    You can also contact attorney Eric Lechtzin of Edelson Lechtzin LLP by calling 844-563-5550 or via e-mail at [email protected].

    ABOUT THE COMPANY: Lantheus Holdings, Inc. is a globally recognized company focused on the development, production, and distribution of advanced diagnostic and therapeutic products, with core expertise in oncology and cardiovascular care.

    THE ALLEGED WRONGDOING: On August 6, 2025, Lantheus reported weaker-than-expected second-quarter results, missing earnings and revenue targets. The company also cut its full-year 2025 revenue and EPS forecasts, citing tougher competition in the PSMA PET imaging market and strategic pullbacks from certain accounts. Revenue for the quarter fell to $378 million, down 4.1%, with PYLARIFY sales dropping 8.3% to $250.6 million—both below projections.

    On this news, the price of Lantheus stock fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.

    ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation in cases alleging violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.

    For more information, please contact:

    Eric Lechtzin, Esq.
    EDELSON LECHTZIN LLP
    411 S. State Street, Suite N-300
    Newtown, PA 18940
    Phone: 844-696-7492 or 215-867-2399 ext. 1
    Email: [email protected]
    Web:  www.edelson-law.com 

    This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

    SOURCE Edelson Lechtzin LLP

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Admin
    • Website

    Related Posts

    cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l’autorisation de mise sur le marché d’Ubeslo® (obicetrapib en monothérapie) et d’Evlarco® (association à dose fixe d’obicetrapib et d’ézétimibe)

    Confusion around cyclosporiasis outbreak as RFK Jr. tries to calm concerns

    Add A Comment
    Leave A Reply Cancel Reply

    Editors Picks

    Most Impressive Team Streaks Of The 21st Century: Where Does 2024-26 Spain Rank?

    NBC’s ‘Stumble’ is a mockumentary about a cheer team with plenty of tumbling runs and heart

    Xiaomi shares post worst week in 3½ years as accidents stoke EV safety concerns

    Judge reverses Trump administration’s cuts of billions of dollars to Harvard University

    Top Reviews
    9.1

    Review: Mi 10 Mobile with Qualcomm Snapdragon 870 Mobile Platform

    By Admin
    8.9

    Comparison of Mobile Phone Providers: 4G Connectivity & Speed

    By Admin
    8.9

    Which LED Lights for Nail Salon Safe? Comparison of Major Brands

    By Admin
    Sg Latest News
    Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
    • Get In Touch
    © 2026 SglatestNews. All rights reserved.

    Type above and press Enter to search. Press Esc to cancel.